immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, conjugated at glutaminyl residues to monomethylauristatin E (MMAE), with a ratio of 1 to 2, via a cleavable linker
HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.antibody_drug_conjugatePhase 3Active
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 65/ 100
Competitive context
187 Active assets in the HER2-positive Breast Cancer cohort.
View all 50 →
Same molecule, other indications
immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, conjugated at glutaminyl residues to monomethylauristatin E (MMAE), with a ratio of 1 to 2, via a cleavable linker is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →